AVITA Medical, Inc.

NasdaqCM:RCEL Stock Report

Market Cap: US$338.2m

AVITA Medical Future Growth

Future criteria checks 5/6

AVITA Medical is forecast to grow earnings and revenue by 51.8% and 32.9% per annum respectively. EPS is expected to grow by 50.4% per annum. Return on equity is forecast to be 9.6% in 3 years.

Key information

51.8%

Earnings growth rate

50.4%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate32.9%
Future return on equity9.6%
Analyst coverage

Good

Last updated24 Dec 2024

Recent future growth updates

AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Is AVITA Medical (NASDAQ:RCEL) Using Debt Sensibly?

Dec 30
Is AVITA Medical (NASDAQ:RCEL) Using Debt Sensibly?

AVITA Medical, Inc.'s (NASDAQ:RCEL) Shares Bounce 26% But Its Business Still Trails The Industry

Dec 03
AVITA Medical, Inc.'s (NASDAQ:RCEL) Shares Bounce 26% But Its Business Still Trails The Industry

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Oct 04
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jul 18
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Jun 18
Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

Apr 12
Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

Feb 02
AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Oct 20
The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Avita Medical appoints James Corbett as CEO

Sep 29

AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal

Sep 12

Avita's burn therapy Recell gets insurance coverage in Japan following approval

Sep 01

AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M

Aug 11

AVITA Medical Is Interesting, But Not Just Yet

Dec 21

AVITA Medical reports preliminary Q2 revenue in-line with consensus

Jan 12

Earnings and Revenue Growth Forecasts

NasdaqCM:RCEL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272561541571572
12/31/20261482964839
12/31/2025101-20-10-911
12/31/202466-54-47-4211
9/30/202460-57-60-52N/A
6/30/202454-50-58-53N/A
3/31/202451-45-52-50N/A
12/31/202350-35-39-38N/A
9/30/202345-34-32-31N/A
6/30/202341-31-25-24N/A
3/31/202337-26-20-19N/A
12/31/202234-27-20-19N/A
9/30/202232-30-21-21N/A
6/30/202230-30-19-18N/A
3/31/202232-29-19-19N/A
12/31/202133-25-19-18N/A
9/30/202131-22-20-19N/A
6/30/202129-27-27-26N/A
3/31/202123-35-29-28N/A
12/31/202018-44-28-27N/A
9/30/202016-49-27-26N/A
6/30/202014-42-24-23N/A
3/31/202012-36-24-23N/A
12/31/201911-28-22-21N/A
9/30/20198-23-22-21N/A
6/30/20195-25-20-19N/A
3/31/20194-22-19-18N/A
12/31/20182-18-14-13N/A
9/30/20181-15-13-13N/A
6/30/20181-13N/A-13N/A
3/31/20181-12N/A-11N/A
12/31/20171-11N/A-9N/A
9/30/20171-10N/A-8N/A
6/30/20171-9N/A-7N/A
3/31/20171-8N/A-6N/A
12/31/20161-7N/A-6N/A
9/30/20161-8N/A-6N/A
6/30/20161-8N/A-6N/A
3/31/20161-8N/A-7N/A
12/31/20151-7N/A-7N/A
9/30/20151-6N/A-5N/A
6/30/20151-6N/A-5N/A
3/31/20151-5N/A-4N/A
12/31/20141-5N/A-4N/A
9/30/20142-5N/A-5N/A
6/30/20143-5N/A-7N/A
3/31/20143-6N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RCEL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: RCEL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RCEL is expected to become profitable in the next 3 years.

Revenue vs Market: RCEL's revenue (32.9% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: RCEL's revenue (32.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RCEL's Return on Equity is forecast to be low in 3 years time (9.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 06:15
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AVITA Medical, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Lyanne HarrisonBofA Global Research
Laura McGuiganB. Riley Securities, Inc.